NAFLD and Physical Exercise: Ready, Steady, Go!

Along with the increase in obesity and type 2 diabetes, the non-alcoholic fatty liver disease (NAFLD) incidence is escalating, thus becoming a leading cause of liver cirrhosis and a significant burden of liver-related outcomes. Since there is no pharmacotherapy available to address the NAFLD, the most effective solutions seem to be lifestyle changes centered on physical activity. Exercise could mediate its beneficial effects directly on the liver and indirectly via extrahepatic pathways, forming a dose-response relationship with NAFLD in terms of prevalence and disease severity. Health-enhancing physical activity (HEPA) levels are mainly needed to exert beneficial effects in obese subjects, while even a small amount of exercise can be beneficial for lean individuals to prevent NAFLD. This mini-review addresses three major points regarding physical activity and NAFLD: prevention, treatment, and extrahepatic benefits, offering recommendations on type and intensity of exercise in liver disease.

Download Full-text

Non-alcoholic fatty liver disease and metabolic syndrome in childhood

Experimental and Clinical Gastroenterology ◽

10.31146/1682-8658-ecg-183-11-51-61 ◽

2020 ◽

Vol 183 (11) ◽

pp. 51-61

Author(s):

N. N. Vlasov ◽

E. A. Kornienko

Keyword(s):

Metabolic Syndrome ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Lifestyle Changes ◽

Alcoholic Fatty Liver ◽

Ample Evidence ◽

Alcoholic Fatty Liver Disease

There is ample evidence that insulin resistance, hyperinsulinemia, and obesity are at the heart of the development of non-alcoholic fatty liver disease (NAFLD). The disease is now considered as the hepatic component of metabolic syndrome (MS).64 children with NAFLD were assessed for metabolic syndrome stigma. An analysis was also made on the state of the problem according to the literature on the general links of the pathogenesis of these conditions, methods of diagnosis and treatment of NAFLD.All components of MS are observed with diﬀerent frequencies in patients with NAFD. This disease, together with type 2 diabetes mellitus, becomes very common diseases in childhood. The incidence of NAFLD in children is constantly growing, it has begun to occur in infants, an outcome in cirrhosis of the liver is possible within childhood, although the prognosis for NAFLD remains deﬁnitely uncertain. Weight loss with a low glycemic index diet, regular exercise, and other lifestyle changes are the mainstay of NAFLD treatment, but not yet very eﬀective for various reasons. In these conditions, it is necessary to increase the role of primary prevention of MS and NAFLD.

Download Full-text

Factors related to Non-Alcoholic Fatty Liver Disease (NAFLD) measures in obese subjects with early Type 2 Diabetes mellitus

Endocrine Abstracts ◽

10.1530/endoabs.61.cd2.1 ◽

2019 ◽

Author(s):

Hadeel Zaghloul ◽

Odette Chagoury ◽

Barbara McGowan ◽

Shahrad Taheri ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Liver Disease ◽

Fatty Liver Disease ◽

Early Type ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Beneficial effects of soluble dietary Jerusalem artichoke (Helianthus tuberosus) in the prevention of the onset of type 2 diabetes and non-alcoholic fatty liver disease in high-fructose diet-fed rats

British Journal Of Nutrition ◽

10.1017/s0007114514001421 ◽

2014 ◽

Vol 112 (5) ◽

pp. 709-717 ◽

Cited By ~ 20

Author(s):

Wan-Ching Chang ◽

Huijuan Jia ◽

Wanping Aw ◽

Kenji Saito ◽

Sumio Hasegawa ◽

...

Keyword(s):

Type 2 Diabetes ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Jerusalem Artichoke ◽

Alcoholic Fatty Liver ◽

Nicotinamide Phosphoribosyltransferase ◽

Beneficial Effects ◽

Alcoholic Fatty Liver Disease

Jerusalem artichoke (JA) has the potential to attenuate lipid disturbances and insulin resistance (IR), but the underlying mechanisms are not well understood. In the present study, we elucidated the physiological responses and mechanisms of JA intervention with a comprehensive transcriptome analysis. Wistar rats were fed a control diet, a 60 % fructose-enriched diet (FRU), or a FRU with 10 % JA (n 6–7) for 4 weeks. An oral glucose tolerance test was carried out on day 21. Liver samples were collected for biochemical and global gene expression analyses (GeneChip® Rat Genome 230 2.0 Array, Affymetrix). Fructose feeding resulted in IR and hepatic TAG accumulation; dietary JA supplementation significantly improved these changes. Transcriptomic profiling revealed that the expression of malic enzyme 1 (Me1), associated with fatty acid synthesis; decorin (Dcn), related to fibrosis; and cytochrome P450, family 1, subfamily a, polypeptide 2 (Cyp1a2) and nicotinamide phosphoribosyltransferase (Nampt), associated with inflammation, was differentially altered by the FRU, whereas dietary JA supplementation significantly improved the expression of these genes. We established for the first time the molecular mechanisms driving the beneficial effects of JA in the prevention of type 2 diabetes and non-alcoholic fatty liver disease. We propose that 10 % JA supplementation may be beneficial for the prevention of the onset of these diseases.

Download Full-text